- Home
- MFIN vs TIL Comparison
MFIN vs TIL Comparison
Compare MFIN & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- TIL
- Stock Information
- Founded
- MFIN 1995
- TIL 2018
- Country
- MFIN United States
- TIL United States
- Employees
- MFIN N/A
- TIL N/A
- Industry
- MFIN Finance: Consumer Services
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- TIL Health Care
- Exchange
- MFIN Nasdaq
- TIL Nasdaq
- Market Cap
- MFIN 207.3M
- TIL 171.7M
- IPO Year
- MFIN 1996
- TIL 2021
- Fundamental
- Price
- MFIN $9.17
- TIL $13.23
- Analyst Decision
- MFIN
- TIL Buy
- Analyst Count
- MFIN 0
- TIL 5
- Target Price
- MFIN N/A
- TIL $114.00
- AVG Volume (30 Days)
- MFIN 43.3K
- TIL 179.4K
- Earning Date
- MFIN 04-30-2025
- TIL 05-20-2025
- Dividend Yield
- MFIN 4.80%
- TIL N/A
- EPS Growth
- MFIN N/A
- TIL N/A
- EPS
- MFIN 1.60
- TIL N/A
- Revenue
- MFIN $316,751,000.00
- TIL N/A
- Revenue This Year
- MFIN N/A
- TIL N/A
- Revenue Next Year
- MFIN $6.21
- TIL N/A
- P/E Ratio
- MFIN $5.72
- TIL N/A
- Revenue Growth
- MFIN 13.93
- TIL N/A
- 52 Week Low
- MFIN $6.48
- TIL $9.62
- 52 Week High
- MFIN $10.50
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- MFIN 60.44
- TIL 44.22
- Support Level
- MFIN $9.00
- TIL $11.97
- Resistance Level
- MFIN $9.34
- TIL $14.67
- Average True Range (ATR)
- MFIN 0.28
- TIL 2.05
- MACD
- MFIN 0.04
- TIL -0.04
- Stochastic Oscillator
- MFIN 79.76
- TIL 17.87
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.